Sestrick Michael Robert 4

4 · BALCHEM CORP · Filed Feb 23, 2024

Form 4

Period: 2024-02-21

SVP & Chief Technology Officer

Transactions

Exercise/Conversion
Common Stock
2024-02-21$76.89/sh+3,900$299,871→ 10,636 total
Exercise/Conversion
Stock Options (right to buy)
2024-02-21−3,500→ 0 total
Exercise: $74.57Exp: 2028-02-15→ Common Stock (3,500 underlying)
Exercise/Conversion
Common Stock
2024-02-21$84.09/sh+3,700$311,133→ 17,836 total
Exercise/Conversion
Common Stock
2024-02-21$74.57/sh+3,500$260,995→ 14,136 total
Sale
Common Stock
2024-02-21$153.21/sh−11,100$1,700,613→ 6,736 total
Exercise/Conversion
Stock Options (right to buy)
2024-02-21−3,900→ 0 total
Exercise: $76.89Exp: 2027-04-18→ Common Stock (3,900 underlying)
Exercise/Conversion
Stock Options (right to buy)
2024-02-21−3,700→ 0 total
Exercise: $84.09Exp: 2029-02-13→ Common Stock (3,700 underlying)

Footnotes (5)

[F1]Exercise of fully vested non-qualified stock options.
[F2]This transaction was executed in multiple sales ranging from $152.7200 to $153.6600 per share, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or any security holder of the issuer full information regarding the number of shares and prices at which the transactions were affected regarding this footnote.
[F3]Stock options that vested 20% on April 18, 2018, 40% on April 18, 2019, and 40% on April 18, 2020, and are exercisable.
[F4]Stock options that vested 20% on February 15, 2019, 40% on February 15, 2020, and 40% on February 15, 2021, and are exercisable.
[F5]Stock options that vested 20% on February 13, 2020, 40% on February 13, 2021, and 40% on February 13, 2022, and are exercisable.

Documents

1 file